Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (342)	3/15/2003 6:52:51 PM
From: nigel bates	Read Replies (1) \| Respond to of 625

Intriguing asterisks... Who is the * in this clause (and how much might the other * be...) ? 8.3 Certain Changes in Control. (a) Notwithstanding any other provision of this Agreement to the contrary, except as set forth in Section 8.3(b), this Agreement shall automatically terminate, without further action by the parties, in the event of (i) a transaction or series of related transactions in which [] is a party and which results in a Change of Control of CAT, or (ii) a transaction or series of related transactions in which CAT is a party and which results in a Change in Control of a person or entity described in clause (i) above; provided, that this Section 8.3(a) shall not apply if CAT shall make to XOMA a cash payment of [] Dollars (US$[]) within five (5) business days following consummation of such transaction or series of related transactions. Schedule 1.14 consists solely of an . Is this the schedule descibing XOMA's rights (and associated royalty obligations) to the CAT libraries ? (The "Library License" refered to in Schedule 1.15)